|
JWH-200 (WIN 55,225)〔 〕 is an analgesic chemical from the aminoalkylindole family that acts as a cannabinoid receptor agonist. Its binding affinity at the CB1 receptor is 42nM, around the same as that of THC,〔Huffman JW, Padgett LW. Recent Developments in the Medicinal Chemistry of Cannabimimetic Indoles, Pyrroles and Indenes. ''Current Medicinal Chemistry'', 2005; 12: 1395-1411.〕 but its analgesic potency ''in vivo'' was higher than that of other analogues with stronger CB1 binding affinity ''in vitro'', around 3 times that of THC but with less sedative effect, most likely reflecting favourable pharmacokinetic characteristics. It was discovered by, and named after, Dr. John W. Huffman. The US DEA temporarily declared JWH-200 a schedule I controlled substance on 1 March 2011 through 76 FR 11075, and permanently instated the same schedule on 9 July 2012 in the Section 1152 of the Food and Drug Administration Safety and Innovation Act.〔(【引用サイトリンク】url=http://www.deadiversion.usdoj.gov/fed_regs/rules/2014/fr0110_10.htm )〕 , the drug is a controlled substance in Canada.〔http://www.gazette.gc.ca/rp-pr/p2/2015/2015-07-29/html/sor-dors192-eng.php〕 ==See also== * JWH-018 * JWH-073 * CP-47,497 * HU-210 * A-796,260 * MEPIRAPIM * WIN 55,212-2 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「JWH-200」の詳細全文を読む スポンサード リンク
|